Testosterone Cypionate Delayed-Onset Side Effects: What Takes Weeks or Months to Appear

Which effects actually take weeks or months?

Injection-site problems arrive around the injection itself: the Depo-Testosterone label lists inflammation and pain at the intramuscular injection site among adverse reactions [4].

Several of the effects below show up on routine testing rather than at the time of the injection. Testosterone cypionate is an oil-soluble ester of testosterone given deep in the gluteal muscle, usually 50 to 400 mg every 2 to 4 weeks [4]. It is absorbed slowly from the oil depot, and the half-life after intramuscular injection is about 8 days [4]. The Depo-Testosterone label gives no onset window for these effects [4], so the figures below come from studies of different lengths.

Hematocrit: the best-documented delayed effect

A network meta-analysis of 29 placebo-controlled randomized trials covering 3,393 men found that intramuscular testosterone enanthate or cypionate raised mean hematocrit by 4.0 percentage points compared with placebo (95% CI 2.9 to 5.1) [1]. Every formulation raised hematocrit; the point estimate was 4.3 percentage points for oral testosterone undecanoate, 3.0 for gel, 1.4 for patch and 1.6 for intramuscular testosterone undecanoate [1].

In one retrospective single-center review of 178 hypogonadal men followed for 3 years, hematocrit exceeded 50% in 66.7% of men on injectable testosterone versus 12.8% on gels and 35.1% on pellets; the injection group was younger (mean 42.5 versus about 54 years), had a higher starting hematocrit, and the study was not randomized [7]. Reviews of the topic say short-acting injectables carry the highest incidence [8], and one review reported a 315% greater risk of erythrocytosis (hematocrit above 0.52) than in controls [9].

The pooled 4.0 percentage point estimate combines enanthate and cypionate, so it is not specific to cypionate [1]. The Depo-Testosterone label notes that increased red cell mass may increase the risk of thromboembolic events [4].

Blood pressure

FDA states that ambulatory blood pressure monitoring studies confirmed a blood pressure increase with all testosterone products, class-wide, and its February 2025 labeling action added a blood pressure warning to products that did not already have one [3]. The Depo-Testosterone label warns that testosterone can increase blood pressure, which can increase cardiovascular risk over time; it says to monitor blood pressure periodically, especially in men with hypertension, and that testosterone products are not recommended in men with uncontrolled hypertension [4].

Fertility and sperm production

Exogenous testosterone inhibits pituitary luteinizing hormone and, at large doses, follicle stimulating hormone, which suppresses sperm production [4]. The Endocrine Society guideline recommends against starting testosterone therapy in men who plan to have children in the near term [10].

Recovery is common but varies. The recovery data come mostly from healthy men on hormonal contraceptive regimens rather than men with hypogonadism: an integrated analysis of 30 studies in 1,549 healthy eugonadal men found a median of 3.4 months for sperm concentration to return to 20 million/mL; 67% recovered within 6 months, 90% within 12 months, 96% within 16 months and 100% within 24 months [11]. Recovery was faster with shorter-acting testosterone, shorter treatment, older age and a higher baseline sperm count [11].

Among men who were already infertile on testosterone, 66 men treated with high-dose hCG plus a selective estrogen receptor modulator after stopping testosterone saw 46 (70%) reach a total motile count above 5 million within 12 months; only 64.8% of the azoospermic men did, versus 91.7% of the cryptozoospermic men, and older age and longer testosterone use predicted slower recovery [5]. In a separate 49-man series using hCG 3,000 units subcutaneously every other day plus clomiphene, tamoxifen, anastrozole or FSH, spermatogenesis returned or improved in 47 men (95.9%) at an average of 4.6 months [12].

Lipids

A meta-analysis of 19 studies in 272 hypogonadal men treated with intramuscular testosterone esters (average 179 mg every 16 days for about 6 months) found small pre-to-post declines: total cholesterol fell 14 mg/dL (95% CI -17 to -11), LDL cholesterol fell 5 mg/dL (-8 to -1), HDL cholesterol fell 4 mg/dL (-5 to -2), and triglycerides were essentially unchanged at -1 mg/dL (-6 to +4) [2]. A smaller comparison in weight-trained men found testosterone cypionate reduced HDL cholesterol without changing the total-to-HDL ratio [13].

Prostate and urinary symptoms

The Endocrine Society guideline recommends monitoring prostate cancer risk during the first year of testosterone therapy [10].

For urinary symptoms specifically, a meta-analysis of 14 randomized trials in 2,029 men found the change in International Prostate Symptom Score on testosterone was not significantly different from placebo [14].

Gynecomastia

The Depo-Testosterone label states that gynecomastia may develop and occasionally persists in men treated for hypogonadism, and it lists gynecomastia among reported adverse reactions [4]. Most gynecomastia results from deficient androgen action or excessive estrogen action in breast tissue: estrogens stimulate breast tissue growth, androgens inhibit it, and aromatase converts androgens to estrogens [15].

Heart attack, stroke and clots

The largest cardiovascular trial of testosterone, TRAVERSE, enrolled 5,246 men aged 45 to 80 with hypogonadism and existing or high risk of cardiovascular disease, but it tested daily 1.62% testosterone gel against placebo gel, not injections [6]. Major adverse cardiovascular events occurred in 7.0% on testosterone versus 7.3% on placebo, hazard ratio 0.96 (95% CI 0.78 to 1.17), meeting noninferiority over a mean follow-up of 33 months [6]. No outcome trial of that size exists for injectable testosterone [6].

The Depo-Testosterone label still carries older language: long-term safety trials for cardiovascular outcomes have not been conducted, epidemiologic studies and randomized trials have been inconclusive, and some studies but not all have reported an increased risk of major adverse cardiovascular events [4]. The same label notes postmarketing reports of deep vein thrombosis and pulmonary embolism in patients using testosterone products such as testosterone cypionate, and says to evaluate for these and discontinue treatment if a venous thromboembolic event is suspected [4].

Monitoring what takes time to appear

The Endocrine Society guideline recommends monitoring symptoms, serum testosterone, hematocrit and prostate cancer risk during the first year of therapy [10]. The Depo-Testosterone label calls for periodic hemoglobin and hematocrit checks with long-term use and periodic blood pressure monitoring, especially in men with hypertension [4].